Mode
Text Size
Log in / Sign up
N/A N=61 Treatment

Minoxidil 2% Solution and Botanical Hair Regimen in Women With Thinning Hair and Female Pattern Hair Loss/Androgenic Alopecia

Female Pattern Hair Loss, Androgenic Alopecia

Enrolled (actual)
61
Serious AEs
0.0%
Results posted
Aug 2023
Primary outcome: Primary: Change From Baseline in Investigator's Rating of Global Photographs at Week 12 — 4.9; 4.9; 4.8; 5.0 Score on a scale

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Treatment: Minoxidil 2% / Botanical Hair Solution for Women (Drug)
Age
Adult · 18+ yrs
Sex
Female
Sponsor
Galderma R&D
Primary completion
Sep 2015

Outcome Measures

OutcomeResultp-value
PRIMARY
Change From Baseline in Investigator's Rating of Global Photographs at Week 12
4.9; 4.9; 4.8; 5.0
SECONDARY
Change From Baseline in Participant Rating at Week 12
5.6; 5.4; 5.1; 5.1; 5.5
SECONDARY
Mean Change From Baseline in Shed Hair Count
4.9
SECONDARY
Number of Participants in Each Response Category Based on Subject Satisfaction Questionnaire
27; 13; 14; 37; 9; 8
SECONDARY
Number of Participants With Adverse Events (AEs)
2

Summary

The purpose of this study is to characterize the effect of Minoxidil 2% Solution and Botanical Hair Solution Regimen in women with thinning hair and female pattern hair loss/androgenic alopecia (Ludwig I and II).

Eligibility Criteria

Key Inclusion Criteria

  • Female patients age 18 to 60 years at the time of enrollment.
  • Women who have self-perceived thinning hair.
  • Women who have presentation of female pattern hair loss/androgenic alopecia (Ludwig I and II).

Key Exclusion Criteria

  • History of allergic reactions or severe intolerance to minoxidil and Botanical Hair Solution product ingredients.
  • Plan to use any other concomitant therapy to treat hair loss, regrowth or volume during the study.

3 Subjects taking or planning to take topical or systemic prescription or OTC medications for treating hair loss and/or hair volume.

  • Any significant history of concurrent medical disease, which in the judgment of the Investigator, would make the subject inappropriate for entry to this study including history of skin disease that may confound study results.
  • Subjects who have recently (within the last 6 months) started the use of hormones for birth control or hormone replacement therapy (HRT). Women currently using hormones for birth control or HRT must have been on a stable dose (6 months or longer) in order to be eligible for the study.
  • Pregnant or breast-feeding females or women planning to become pregnant during the course of the study
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02460497). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search